Orexin-A is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of Orexin-A is rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes. This means dosing single dose in research protocols is typical to maintain stable levels. The half-life directly affects how long Orexin-A remains active and influences optimal injection timing.
What Is the Half-Life of Orexin-A?
The half-life of Orexin-A is rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes. This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer Orexin-A to maintain therapeutic blood levels.
What Does Orexin-A's Half-Life Mean for Dosing?
With a half-life of rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes, Orexin-A requires dosing single dose in research protocols to maintain stable levels. The standard dosage of not established for human peptide administration via intranasal (experimental human), intracerebroventricular (animal studies) accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, Orexin-A reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For Orexin-A, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject Orexin-A?
Optimal timing depends on your research goals. A half-life of rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (single dose in research protocols) for more stable levels throughout the day.
How Does Orexin-A's Half-Life Compare to Similar Peptides?
Orexin-A is a Neuropeptide hormone. Its half-life of rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your Orexin-A Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Orexin-A.
Open Calculator →Bottom Line: Orexin-A Half-Life and Dosing
Orexin-A has a half-life of rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes, supporting the standard protocol of not established for human peptide administration dosed single dose in research protocols over single dose protocols; no established multi-week cycles.
Read our Orexin-A dosage guide for complete protocol details.
Complete Guide
Orexin-A : Benefits, Dosage, Side Effects & Research
Related Reading
- Orexin-A Dosage Guide
- Orexin-A Benefits
- Orexin-A Side Effects
- Orexin-A Stacking Guide
- Orexin-A Cycle Guide
- Orexin-A Research
Research-Grade Sourcing
If you're going to research Orexin-A, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Orexin-A?
Orexin-A (Hypocretin-1) is a Neuropeptide hormone. Naturally occurring peptide synthesized in the hypothalamus, regulating sleep-wake cycles and arousal. It is researched for increased wakefulness and arousal, cognitive function in narcolepsy, pain modulation.
What is the recommended Orexin-A dosage?
Common dosages: not established for human peptide administration administered single dose in research protocols via intranasal (experimental human), intracerebroventricular (animal studies). Cycle length: single dose protocols; no established multi-week cycles. Half-life: rapidly degraded peripherally; central CSF half-life estimated 10-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of Orexin-A?
Limited human safety data. Potential increased heart rate and blood pressure. Poor blood-brain-barrier penetration limits peripheral dosing.
Is Orexin-A safe?
Orexin-A has shown a preliminary safety profile in research. Not FDA-approved. Research use only. Development focus has shifted to small molecule receptor agonists. All research should follow appropriate safety protocols.